How Is Fatigue Treated in Myotonic Dystrophy Type 1?
At a Glance
Fatigue in myotonic dystrophy (DM1) is treated by first managing nighttime breathing issues with a BiPAP machine. If daytime sleepiness persists, doctors may prescribe medications like modafinil. However, this requires strict clearance from a cardiologist due to DM1-related heart risks.
In this answer
4 sections
It is incredibly common to feel constantly exhausted when you have Steinert myotonic dystrophy (DM1). This overwhelming tiredness usually happens for two distinct reasons: breathing muscle weakness that disrupts your sleep at night, and direct changes to your brain’s sleep-wake control center [1][2]. The short answer is yes, there are wake-promoting medications (like modafinil) that can help you stay alert during the day [3][4]. However, because DM1 carries a high risk of dangerous heart rhythm problems, you must undergo a sleep study and get strict clearance from a cardiologist before you can safely take these medications [5][6][7]. Because this process involves multiple specialists, your neurologist or neuromuscular specialist will typically act as the coordinator for your care [8].
Understanding Why You Are So Tired
In DM1, exhaustion is usually “multifactorial,” meaning it comes from several different issues working together [1][7]. To address the problem correctly, your medical team must determine which factors are driving your exhaustion:
- Respiratory-Driven Fatigue: DM1 often weakens the diaphragm and other breathing muscles. This can lead to obstructive sleep apnea (where your airway collapses temporarily) or nocturnal hypoventilation (where your breathing is too shallow to clear out carbon dioxide) [2][9]. Even if you think you slept for 10 hours, poor oxygen exchange means your brain never got deep, restorative sleep.
- Central Nervous System (CNS) Sleepiness: DM1 directly affects the brain, altering neurotransmitters and causing structural changes in areas that regulate sleep and wakefulness [1][10][7]. This causes Excessive Daytime Sleepiness (EDS), where you feel an uncontrollable urge to sleep during the day regardless of how well you slept at night.
- Apathy vs. Fatigue: It is also important to recognize apathy (a lack of motivation or emotional drive to do things), which is a distinct symptom caused by brain changes in DM1 [11]. This is different from physical fatigue, which is a feeling of depleted energy linked to muscle weakness and low mood [11][12].
Step 1: The Sleep Study and Breathing Support
Before prescribing any daytime stimulants, doctors must rule out or treat nighttime breathing issues [13][7]. You will typically need a polysomnography (an overnight sleep study) [13].
If the study shows sleep-disordered breathing, the standard treatment is Non-Invasive Ventilation (NIV), such as a BiPAP machine (Bilevel Positive Airway Pressure) [2][14]. Unlike a standard CPAP machine which primarily just keeps the airway open, a BiPAP actively assists your weakened muscles in pushing out built-up carbon dioxide [15].
Getting used to sleeping with a BiPAP can be frustrating at first and requires some trial and error [14]. However, it is worth sticking with: for many patients, consistently using their BiPAP machine drastically reduces their daytime fatigue without the need for medication [2][15].
Step 2: The Mandatory Heart Check
You should never start a stimulant or wake-promoting medication without a thorough evaluation from a cardiologist.
Heart rhythm problems (cardiac arrhythmias) and electrical conduction defects are a hallmark of DM1 and are a leading cause of mortality in the disease [16][6][17]. Medications used for sleepiness have “sympathomimetic” effects—meaning they stimulate the nervous system in ways that can increase heart rate or alter electrical signals [5][6]. In a heart already vulnerable to rhythm disturbances due to DM1, these medications could trigger dangerous cardiovascular events [5][6].
Before moving on to medications, you will need:
- An Electrocardiogram (EKG) to check your heart’s current electrical activity [5].
- Likely a Holter monitor (a wearable device that tracks your heart rhythm for 24-48 hours) to catch hidden arrhythmias [16][18].
- Direct clearance from a cardiologist who is familiar with DM1 [19].
Step 3: Medications and Therapies for Daytime Sleepiness
If your breathing is well-managed and your heart is cleared by a cardiologist, your doctor may prescribe wake-promoting medications to treat CNS-driven EDS [7][20].
- Modafinil and Armodafinil: These are standard wake-promoting agents used to improve alertness. Studies show they can help reduce self-reported sleepiness in DM1 patients [3][21][20]. Common side effects include headache, anxiety, or insomnia, which your doctor will monitor [8].
- Pitolisant or Methylphenidate: These are other types of stimulant medications that may be considered if modafinil is ineffective or not tolerated [3][22].
For patients dealing with severe physical fatigue or lack of motivation, Cognitive Behavioral Therapy (CBT) may also be recommended [23]. Suggesting CBT is not meant to imply your fatigue is “all in your head.” Rather, it helps you develop practical strategies for energy conservation, pacing yourself, and coping with the emotional toll of chronic exhaustion [23][24].
Note on Expectations: Booking a sleep study, adjusting to a BiPAP, seeing a cardiologist, and finding the right medication dosage can take several months. Knowing this upfront can help you manage your expectations. Tackling these steps in order is the safest, most effective path to getting your energy back.
Common questions in this guide
Why do I feel so tired with myotonic dystrophy?
Do I need a sleep study if I have DM1?
Will a standard CPAP machine help my sleepiness?
Can I take medication like modafinil for daytime sleepiness?
What is the difference between fatigue and apathy in DM1?
Questions for Your Doctor
6 questions
- •Can you refer me to a sleep specialist or pulmonologist who is familiar with neuromuscular disorders?
- •Can we schedule a sleep study to see if my exhaustion is caused by sleep apnea or nighttime hypoventilation?
- •If I am already using a BiPAP, how can we check if my settings need to be adjusted to better improve my daytime energy?
- •What is my current cardiac risk profile, and is it safe for me to trial a wake-promoting medication like modafinil?
- •Do you work with a cardiologist who understands the specific conduction defects associated with myotonic dystrophy?
- •How can we differentiate whether I am experiencing physical fatigue, excessive daytime sleepiness, or neurological apathy?
Questions for You
4 questions
- •Do I frequently wake up with morning headaches or feel completely unrefreshed, even after a full night's sleep?
- •How consistent am I with using my breathing machine every single night, and what makes it difficult?
- •Do I feel an uncontrollable physical urge to fall asleep during the day, or do I feel a lack of motivation and energy to start tasks?
- •When was my last comprehensive heart evaluation, including an EKG or Holter monitor?
Related questions
References
References (24)
- 1
Cognitive Deficits, Apathy, and Hypersomnolence Represent the Core Brain Symptoms of Adult-Onset Myotonic Dystrophy Type 1.
Miller JN, Kruger A, Moser DJ, et al.
Frontiers in neurology 2021; (12()):700796 doi:10.3389/fneur.2021.700796.
PMID: 34276551 - 2
Sugammadex is changing the paradigm in neuromuscular blockade in patients with myotonic dystrophy.
Teixeira J, Matias B, Ferreira I, et al.
Journal of perioperative practice 2019; (29(10)):337-340 doi:10.1177/1750458919838412.
PMID: 30888938 - 3
Congenital and childhood myotonic dystrophy: Current aspects of disease and future directions.
Ho G, Cardamone M, Farrar M
World journal of clinical pediatrics 2015; (4(4)):66-80 doi:10.5409/wjcp.v4.i4.66.
PMID: 26566479 - 4
Brain Pathogenesis and Potential Therapeutic Strategies in Myotonic Dystrophy Type 1.
Liu J, Guo ZN, Yan XL, et al.
Frontiers in aging neuroscience 2021; (13()):755392 doi:10.3389/fnagi.2021.755392.
PMID: 34867280 - 5
Efficacy of methylphenidate treatment in childhood myotonic dystrophy type 1 and comorbid attention deficit hyperactivity disorder: A case report using eye tracking assessment.
Sweere DJJ, Hendriksen JGM, Jeroen Vermeulen R, Klinkenberg S
Brain & development 2024; (46(2)):118-121 doi:10.1016/j.braindev.2023.11.004.
PMID: 38007339 - 6
Association Between Mutation Size and Cardiac Involvement in Myotonic Dystrophy Type 1: An Analysis of the DM1-Heart Registry.
Chong-Nguyen C, Wahbi K, Algalarrondo V, et al.
Circulation. Cardiovascular genetics 2017; (10(3)) doi:10.1161/CIRCGENETICS.116.001526.
PMID: 28611030 - 7
Excessive daytime sleepiness in myotonic dystrophy: a narrative review.
Hoxhaj D, Pascazio A, Maestri M, et al.
Frontiers in neurology 2024; (15()):1389949 doi:10.3389/fneur.2024.1389949.
PMID: 39011358 - 8
Consensus-based care recommendations for adults with myotonic dystrophy type 1.
Ashizawa T, Gagnon C, Groh WJ, et al.
Neurology. Clinical practice 2018; (8(6)):507-520 doi:10.1212/CPJ.0000000000000531.
PMID: 30588381 - 9
Respiratory dysfunction in myotonic dystrophy type 1: A systematic review.
Hawkins AM, Hawkins CL, Abdul Razak K, et al.
Neuromuscular disorders : NMD 2019; (29(3)):198-212 doi:10.1016/j.nmd.2018.12.002.
PMID: 30765255 - 10
Clinical and neuroradiological correlates of sleep in myotonic dystrophy type 1.
Hamilton MJ, Atalaia A, McLean J, et al.
Neuromuscular disorders : NMD 2022; (32(5)):377-389 doi:10.1016/j.nmd.2022.02.003.
PMID: 35361525 - 11
Six Serum miRNAs Fail to Validate as Myotonic Dystrophy Type 1 Biomarkers.
Fernandez-Costa JM, Llamusi B, Bargiela A, et al.
PloS one 2016; (11(2)):e0150501 doi:10.1371/journal.pone.0150501.
PMID: 26919350 - 12
Perceived fatigue in myotonic dystrophy type 1: a case-control study.
Winblad S, Lindberg C
BMC neurology 2019; (19(1)):45 doi:10.1186/s12883-019-1280-z.
PMID: 30922263 - 13
[Multiorgan manifestations in myotonic dystrophy type 1].
Varga D, Pál E
Orvosi hetilap 2019; (160(37)):1447-1454 doi:10.1556/650.2019.31505.
PMID: 31495190 - 14
Effect and impact of mechanical ventilation in myotonic dystrophy type 1: a prospective cohort study.
Boussaïd G, Prigent H, Laforet P, et al.
Thorax 2018; (73(11)):1075-1078 doi:10.1136/thoraxjnl-2017-210610.
PMID: 29572271 - 15
Sleep-disordered breathing and effects of non-invasive ventilation on objective sleep and nocturnal respiration in patients with myotonic dystrophy type I.
Spiesshoefer J, Runte M, Heidbreder A, et al.
Neuromuscular disorders : NMD 2019; (29(4)):302-309 doi:10.1016/j.nmd.2019.02.006.
PMID: 30898523 - 16
Cardiac Pathology in Myotonic Dystrophy Type 1.
Mahadevan MS, Yadava RS, Mandal M
International journal of molecular sciences 2021; (22(21)) doi:10.3390/ijms222111874.
PMID: 34769305 - 17
Cardiac Involvement and Arrhythmias Associated with Myotonic Dystrophy.
McBride D, Deshmukh A, Shore S, et al.
Reviews in cardiovascular medicine 2022; (23(4)) doi:10.31083/j.rcm2304126.
PMID: 36177340 - 18
[Myotonic dystrophy type 1 - a rare cause of bradycardia in the young].
Kataja Knight A, Tidehag L, Mattsson G, Magnusson P
Lakartidningen 2020; (117()).
PMID: 31961442 - 19
Comprehensive Cardiovascular Management of Myotonic Dystrophy Type 1 Patients: A Report from the Italian Neuro-Cardiology Network.
Russo V, Antonini G, Massa R, et al.
Journal of cardiovascular development and disease 2024; (11(2)) doi:10.3390/jcdd11020063.
PMID: 38392277 - 20
Sleepiness and Sleep-related Breathing Disorders in Myotonic Dystrophy and Responses to Treatment: A Prospective Cohort Study.
West SD, Lochmüller H, Hughes J, et al.
Journal of neuromuscular diseases 2016; (3(4)):529-537 doi:10.3233/JND-160191.
PMID: 27911338 - 21
Psychostimulants for hypersomnia (excessive daytime sleepiness) in myotonic dystrophy.
Annane D, Laberge L, Gallais B, Chevret S
The Cochrane database of systematic reviews 2024; (11()):CD003218 doi:10.1002/14651858.CD003218.pub3.
PMID: 39555632 - 22
MBNL overexpression rescues cardiac phenotypes in a myotonic dystrophy type 1 heart mouse model.
Hu RC, Zhang Y, Nitschke L, et al.
The Journal of clinical investigation 2025; (135(7)).
PMID: 39932794 - 23
Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial.
Okkersen K, Jimenez-Moreno C, Wenninger S, et al.
The Lancet. Neurology 2018; (17(8)):671-680 doi:10.1016/S1474-4422(18)30203-5.
PMID: 29934199 - 24
Look at the cognitive deficits in patients with myotonic dystrophy type 1: an exploratory research on the effects of virtual reality.
Maresca G, Portaro S, Naro A, et al.
International journal of rehabilitation research. Internationale Zeitschrift fur Rehabilitationsforschung. Revue internationale de recherches de readaptation 2020; (43(1)):90-94 doi:10.1097/MRR.0000000000000384.
PMID: 31851022
This page explains fatigue and sleepiness management in myotonic dystrophy for educational purposes. Always consult your neurologist and cardiologist before starting any new treatments or wake-promoting medications.
Get notified when new evidence is published on Steinert myotonic dystrophy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.